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Abstract
Blood safety in sub-Saharan Africa is jeopardized by multiple and diverse factors, including the predominance of high-risk family/replacement
donors and the high prevalence of transfusion-transmissible infections (TTIs). Thus, stringent diagnostic strategies are vital. Western
blotting is costly and technically demanding, and nucleic acid testing technologies, which have been reported to reliably reduce the rate of
TTI, are not available in resource-limited settings. Therefore, there is a need for reliable and affordable testing alternatives in these settings.
Rapid diagnostic testing has been widely adopted in developing countries, but, for effectiveness in blood safety, highly sensitive tests and the
strict selection of low-risk blood donors are indispensable. Although the pre-serological window period remains a source of residual risk for
transmission of TTIs during blood transfusion, the combination antigen–antibody rapid tests could contribute signiﬁcantly to shortening the
window period. Thus, despite its limitations, rapid diagnostic testing continues to contribute signiﬁcantly to blood safety, as a cost-effective
means of enhancing screening for TTIs and reducing their transmission in resource-limited rural settings.
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Introduction
Screening for blood-transmissible pathogens is a critical aspect
of blood safety. Where effective screening programmes exist,
the risk of transmission of transfusion-transmissible infections
(TTIs) has been reported to progressively and signiﬁcantly
decrease [1,2]. This has been clearly demonstrated in western
countries, where the most reliable screening methods are
used, including nucleic acid ampliﬁcation testing technologies,
which allow for very early detection of various infectious
agents [3]. Other conﬁrmatory tests often used include
western blot assays, line immunoassays (LIAs), recombinant
immunoblot assays, indirect ﬂuorescent antibody assays, and
ELISAs. Unfortunately, these technologies are only feasible in
major African cities, where external funding is obtainable.
Paradoxically, blood safety in these resource-limited set-
tings (RLSs), and especially in sub-Saharan Africa (SSA), is
compromised by several factors [4], including the highest
prevalence of TTIs and the chronic shortage of reagents for
their diagnosis. The major TTIs described include human
immunodeﬁciency virus (HIV), hepatitis B virus (HBV), hepa-
titis C virus (HCV), syphilis, and malaria. Hence, the WHO
recommends that all blood for transfusion in RLSs be
mandatorily screened for HIV, HBV, HCV, and syphilis [5],
with either a combination of HIV antigen–antibody or HIV
antibodies, hepatitis B surface antigen (HBsAg), a combination
of HCV antigen–antibody or HCV antibodies, and speciﬁc
treponemal antibodies, respectively [6]. Despite this, several
countries are unable to screen all donated blood for one or
more of these markers [5].
Another major issue concerns voluntary, non-remunerated
and regular blood donors, who are reported to have the
lowest rates of TTI [7]. However, in these RLSs, family/
replacement and, in some cases, paid donors, with high risks
for TTI, provide 70–90% of donations [4,8–10]. Although these
family and replacement donors are more cost-effective for
RLSs [8,11] and more easily manageable than a centralized
‘western model’ based on a 100% voluntary, non-remunerated
and regular blood donor system [8,12], it must be emphasized
that increased blood safety is only achievable with low-risk
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blood donors. In 2010, Choudary reported a 1–2 per 1000 risk
for blood recipients of contaminated blood of acquiring viral,
bacterial or parasitic infections [13], even with very low
pathogen load. Hence, it is vital to meticulously select safe
blood donors and ensure the use of quality screening methods.
Even in RLSs, the use of affordable alternative screening
methods such as rapid diagnostic testing will contribute
signiﬁcantly to blood safety, including in the more rural
settings, where small numbers of daily tests (e.g. <20 samples/
day) are performed. A recent study in Tete, in Mozambique,
has clearly illustrated the need for and effectiveness of the
consistent use of quality-assured rapid diagnostic tests (RDTs)
in screening donated blood [14].
Rapid diagnostic testing is currently available for the
screening of various pathogens, including HIV, HBV, HCV,
syphilis and malaria infections, and newer technologies
are being developed continuously. These are simple instru-
ment-free assays that may be performed by personnel who
have received very little training, and no laboratory facilities
are required. The test kits are generally low in cost, with
prices in the WHO bulk procurement scheme ranging from US
$0.40 to US$2.00 per test. In addition, the kits are easy to
store (room temperature, with no need for refrigeration), and
require very short intervals (10–30 min) to provide results.
These characteristics have rendered rapid diagnostic testing
especially user-friendly in RLSs. Consequently, rapid diagnostic
testing has been integrated into, and served as a point-of-care
tool, in various healthcare programmes. Alternative testing
strategies and algorithms have also been developed for
pathogen screening and conﬁrmation based on quality rapid
diagnostic testing, both for transfusion and other services,
especially where only few blood units are collected [15]. A
typical scenario in SSA would be blood transfusion; this is often
an urgent clinical decision requiring immediate results, which
rapid diagnostic testing could provide within 30 min. Thus,
rapid diagnostic testing is indispensable in such situations.
This review focuses on alerting clinicians and heads of
transfusion services to the current pitfalls of transfusion
services in RLSs, and the use of rapid diagnostic testing as an
alternative for providing safe blood in these settings.
Pitfalls in Blood Transfusion Services in RLSs
Blood transfusion services in RLSs, especially in SSA, are
inadequate in all aspects of the blood safety chain, from policy
development through blood donor selection to the appropriate
use of blood products [16]. In 2006, only 22 of the 46 member
states in the African Region of the WHO had developed
policies for blood transfusion [17], and implementation has
been equally slow. The lack of national coordination of
designated blood transfusion budgets, trained staff, donor
recruitment programmes and national testing strategies, the
lack of national guidelines for the clinical use of blood and the
lack of haemovigilance and quality management programmes all
contribute to hampering blood safety in these RLSs. In addition,
the high disparity in funding systems and ﬁnancing mechanisms
is an issue of concern. Some RLSs have beneﬁted from external
funding, including the President’s Emergency Plan for AIDS
Relief (PEPFAR) and from the CDC, Atlanta, and hence may
boast of reasonably reliable transfusion services, but the issue
of sustainability post-funding remains.
Performance and Limitations of Rapid
diagnostic Testing in Blood Transfusion
Safety in RLSs
Principles of rapid diagnostic testing
RDTs are based on different principles, of which four major
types have been described (see Editorial). Many of these tests
have an internal sample addition control that validates each
test run. Whole blood, serum, plasma, and even ﬁnger-prick
blood specimens, saliva or oral ﬂuids have been used with
these tests. Various test kits based on these principles are
commercially available for use in RLSs, and lateral-ﬂow
immunochromatographic assays seem to be most current.
A few organizations, including the WHO and the US Food
and Drug Administration, carry out evaluations of test kits
based on criteria set by the WHO. They include: the speed
with which results are obtained (<30 min); accuracy (sensitiv-
ity and speciﬁcity of >99% and >98%, respectively); minimal
specimen volume; variability in specimen type (whole blood,
plasma, and serum); ease of use (no specialized equipment);
and stability of the reagents at ambient temperatures or
between 2°C and 8°C [18]. Details of some currently available
quality RDTs, based on these criteria, are shown in Table 1
[19–21]. For further reading on RDT, see Table 2.
RDTs for HIV
Many RDTs for HIV utilize the gp41 antigen as the target
antigen for detecting HIV. Serological markers such as
antibodies to HIV-1, including group O, to HIV-2, and to the
p24 antigen, which appears early in the infection, are detected,
as well as viral RNA when possible. Thus, the diagnostic tests
contain antigens to speciﬁc HIV proteins of one group or
subtype, hence may vary in performance, according to the [9]
HIV strain being detected [22].
High rates of false-positive HIV results have been reported
in several studies [23–25], usually because of the relatively low
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speciﬁcities of some test kits, despite very high sensitivities.
Low speciﬁcities of HIV antibody screening tests may also
result from tropical infections that cause B-cell activation, such
as human African Trypanosoma infections, resulting in false-
positive results [26]. False-negative results also represent a
challenge [25], exacerbated by poor staff training and subjec-
tivity in interpreting faint RDT results [24].
RDTs for HBV
The earliest HBV serological marker is its surface antigen
HBsAg, but others develop in the course of the infection. Thus,
one main target in HBV screening includes serology of HBsAg;
however, routine screening for its core antibody (anti-HBc) is
not recommended, because of non-speciﬁc results [6].
Most RDTs for HBV are based on agglutination or lateral-
ﬂow principles, and qualitatively detect the presence of HBsAg.
These are also available for detecting other HBV serological
markers, such as the HBe antigen (HBeAg) and antibodies to
HBs, HBc and HBe. Various improvements are being made to
these lateral-ﬂow assays for HBV. As declared in one analysis
in 2008 [27], ‘the major challenge for HBsAg rapid tests is to
detect the low levels of the target antigen that are present in a
relatively high proportion of asymptomatic blood donors in
order to achieve a clinical sensitivity similar to that of enzyme
immune-assays (EIA)’. With the wide genetic diversity in HBV
(genotypes A–H), there is high antigenic variation of HBsAg,
and a need for high antigen concentrations of some variants in
order for them to be detected with commercial kits. An
TABLE 1. Some available quality rapid diagnostic test kits for transfusion-transmissible infections [19–21] (the selection of
examples is based mainly on high sensitivity and/or speciﬁcity)
Name Manufacturer Pathogen Sensitivity (%) Speciﬁcity (%) Performance evaluation criteria
Determine HIV1/2 Abbott Laboratories HIV 100 99.6 WHO [19]
HIV 1/2 STAT-PAK Chembio Diagnostic Systems HIV 99.7 99.3 WHO [20]
HIV 1/2 STAT-PAK Dipstick Chembio Diagnostic Systems HIV 99.0 100 WHO [20]
Uni-Gold HIV-1/HIV-2 Trinity Biotech HIV 100 100 WHO [20]
Immunocomb II HIV 1&2 BiSpot Orgenics HIV 100 99.7 WHO [20]
Retrocheck HIV 1&2/Core HIV 1&2 Qualpro Diagnostics/Core Diagnostics HIV 100 99.1 WHO [20]
DoubleCheckGold HIV 1&2 Orgenics HIV 100 99.3 WHO [20]
OraQuick HIV-1/2 OraSure Technologies HIV 100 99.2 WHO [20]
Multispot HIV 1/2 Bio-Rad Laboratories HIV 100 99.93 FDA [19]
Determine Syphilis TP Abbott Laboratories Syphilis 100 98.6 WHO [19]
HCV Tri Dot J. Mitra & Co. HCV 100 91.5 WHO [19]
HCV SpoT Genelabs Diagnostics HCV 100 93.7 WHO [19]
SeroCard HCV Trinity Biotech HCV 98.5 100 WHO [19]
Determine HBsAg Abbott Laboratories HBV 100 100 WHO [19]
Dainascreen Abbott Laboratories HBV 100 100 WHO [19]
SD BioLine HBsAg (One Step HBsAg Test) Standard Diagnostics HBsAg 97.95 100 ICBS [21]
Assure HBsAg Rapid Test MP Biomedicals Asia Paciﬁc HBsAg 97.95 100 ICBS [21]
Quick Chaser HBsAg Mizuho Medy HBsAg 97.95 100 ICBS [21]
FDA, Food and Drug Administration; HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus; HCV, hepatitis C virus; HIV, human immunodeﬁciency virus; ICBS, International
Consortium for Blood Safety.
TABLE 2. References on quality rapid diagnostic tests for further reading
Pathogen References
HIV Point-of-Care HIV Testing Using Rapid HIV Test Kits: Guidance for Health-Care Professionals
www.who.int/diagnostics_laboratory/evaluations/hiv/en/
Rapid immunochromatographic detection by ampliﬁcation of the colloidal gold signal
www.who.int/diagnostics_laboratory/evaluations/hiv/en/
HIV
Trypanosoma
http://jcm.asm.org/content/48/8/2836.full.pdf+html
Syphilis Sena AC, White BL, Sparling PF. Novel treponema pallidum serologic tests: a paradigm shift in syphilis screening for the 21st century. Clin Infect
Dis 2010; 51: 700–708.
cid.oxfordjournals.org/content/51/6/700.full
Diagnostic testing for syphilis
www.uptodate.com/contents/diagnostic-testing-for-syphilis
HCV WHO Hepatitis C test kit evaluations
www.who.int/diagnostics_laboratory/evaluations/hepc/en/
Smith BD, Drobeniuc J, Jewett A et al. Evaluation of three rapid screening assays for detection of antibodies to hepatitis C virus. J Infect Dis 2011;
204: 825–831.
www.natap.org/2011/HCV/JDis2011-Smith-825-31.pdf
O’Connell RJ, Gates RG, Bautista CT et al. Laboratory evaluation of rapid test kits to detect hepatitis C antibody for use in predonation screening
in emergency settings. Transfusion 2012; Jul 23. doi: 10.1111/j.1537-2995.2012.03770.x. [Epub ahead of print]
CBS: HCV test kit (2006)
http://www.icbs-web.org/page30.html
HBsAg http://www.rapid-diagnostics.org/ﬁles/HBV-Manufacturers-website.rtf
www.who.int/diagnostics_laboratory/evaluations/hepb/en/
http://www.icbs-web.org/page30.html (2010)
HIV, HCV, HBV, syphilis WHO 2010, http://www.who.int/bloodsafety/ScreeningDonatedBloodforTransfusion.pdf
HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus; HCV, hepatitis C virus; HIV, human immunodeﬁciency virus.
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evaluation of various HBsAg assays using panels from the
International Consortium on Blood Safety showed low
analytical sensitivities of RDTs for HBsAg detection, as shown
by 13 of 19 RDTs not detecting International Consortium on
Blood Safety dilutions as positive, despite having high speciﬁc-
ities [21]. Thus, sensitivity remains an issue for current HBV
RDTs (HBsAg), despite excellent speciﬁcity. This emphasizes
the continuous quest to improve the sensitivity of RDTs,
which is indispensable for blood safety. An example of such an
improvement is the new HBsAg rapid immunochromatograph-
ic assay based on the signal ampliﬁcation system, which has
been evaluated and shown to have enhanced sensitivity [27].
RDTs for HCV
The laboratory diagnosis of HCV infection consists of detect-
ing anti-HCV antibodies in the blood, followed by the
conﬁrmation of reactive samples with LIAs. Anti-HCV anti-
bodies are detectable in approximately 90% of cases by
12 weeks of infection [28]. The number of available HCV
antibody tests, including simple/rapid tests, has increased in
recent years, but rapid diagnostic testing for HCV has been
reported to be less sensitive than enzyme immunoassays
(EIAs) [29,30]. A recent evaluation of anti-HCV RDT perfor-
mance by Smith et al. [31] conﬁrmed low sensitivities, but,
interestingly, the recently US Food and Drug Administration-
approved OraQuick HCV Rapid Antibody Test was reported
to perform comparably to EIA techniques [32]. Nevertheless,
serological screening has considerably reduced HCV trans-
mission through blood transfusion [6].
RDTs for screening for syphilis
Several methods are used for the diagnosis of syphilis; some
require the use of speciﬁc treponemal antigens, some use rapid
point-of-care tests, and others use EIAs as well as chemilumi-
nescence assays. Non-treponemal tests are also used, including
the old rapid plasma reagin test, which uses phospholipid (non-
treponemal) antigens, the Venereal Disease Research Labora-
tory test, and the toluidine red unheated serum test, all of
which are not only low in cost, but are also easy to perform.
However, they require treponemal-based conﬁrmation,
because detectable antibodies can be produced by other
inﬂammatory conditions, and their sensitivities vary with the
type of test and stage of infection. Some treponemal tests
include microhaemagglutination assays, particle agglutination
assays, haemagglutination assays, and the ﬂuorescent trepone-
mal antibody absorption assay.
Several rapid syphilis tests are available worldwide that may
be used with serum, plasma, or whole blood specimens [33].
These are highly sensitive and speciﬁc [33,34], as most detect
both IgM and IgG. Although RDTs used in screening for syphilis
infection have been reported to be highly sensitive, they
cannot distinguish between active and treated syphilis, so false-
positive reactions are possible [35]. Thus, positive results need
to be conﬁrmed with quantitative non-treponemal testing to
determine recent infection and response to therapy.
Conﬁrmation testing
The conﬁrmation of RDT results is of relevance for issuing
accurate results to blood donors, as well as for purposes of
acquiring accurate epidemiological data; for blood safety,
sensitivity is of the utmost importance. Where no established
quality systems exist in RLSs, conﬁrmation is not necessary,
because all reactive blood units should always be discarded.
However, in settings with an established quality system, the
WHO recommends repeat testing, in duplicate, of the same
sample and with the same assay before conclusions are drawn
[6]. Furthermore, repeat testing may be performed with an
alternative assay, either an RDT or an EIA [24,36]. Indeed, the
WHO established an HIV diagnostic algorithm that has been
adapted in various countries of RLSs for conﬁrmation of
antibodies to HIV. It must be noted here that conﬁrmation
rates are generally very low for HCV [37], although the rate of
conﬁrmation of most HBsAg RDT results is >90%, suggesting
that conﬁrmation with an alternative screening assay may not
be necessary. More recently, a dual-path platform RDT based
on the parallel detection of both treponemal and non-
treponemal lines was evaluated in China, and showed reason-
ably high sensitivities and speciﬁcities with different specimen
types (whole blood, plasma, and ﬁnger-prick blood), thus
serving as both a screen and a conﬁrmatory test [38]. This is a
promising alternative for syphilis diagnosis in RLSs.
The main issue with TTI transmission is the window period,
which allows for residual risks in blood transfusion, and
combination antigen–antibody RDTs would shorten this [39],
although they may still be costly for RLSs. In any case, very
sensitive assays for TTIs are crucial for blood safety.
Discussions and Conclusions
Today, western blotting remains costly and technically cum-
bersome for RLSs, and nucleic acid ampliﬁcation testing
remains inaccessible to and unaffordable for most countries,
especially of SSA. In this light, testing strategies including simple
rapid tests are indispensable, with the possibility of using
serum, plasma, whole blood and even saliva in screening for
different pathogens.
RDTs are not only cheaper than algorithms based on ELISA
and western blot methods, but have also been reported to
have comparable effectiveness [40,41]. Furthermore, a few
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systematic evaluations of rapid HIV tests with non-B subtypes
of HIV-1 group M and group O and HIV-2 have established
that most tests adequately detect all subtypes of group M, but
that their performance is more variable with group O and
HIV-2 strains [22]. Interestingly, others have reported low
levels of analytical sensitivity for RDTs [23,42]. In a ﬁeld trial in
Uganda, using an algorithm of three rapid HIV tests, of the
weakly positive results on one or more of the three tests,
94.1% were negative or indeterminate on EIA or western
blotting [23], further raising issues of sensitivity. Indeed, in one
study in Cameroon, Tagny et al. demonstrated that using a
combination antigen–antibody test could prevent 55 HIV
transmissions per 10 000 donations of blood missed by RDTs
[43]. In another study, conducted in KwaZulu Natal (South
Africa), an increase was observed in the sensitivity of rapid
diagnostic testing, from 68.7% to 93.5%, after a change of test
brands [44]. Unfortunately, these variations in performance
between RDTs are inﬂuenced by their quality, which depends
on their costs; the lowest-performing assays tend to be low-
cost, because they are neither evaluated nor approved by
credible institutions. The lack of rigorous standards in the
laboratory and untrained staff also contribute to inaccurate
RDT results [44].
Recent WHO data indicated that, of 155 countries perform-
ing 100% screening forHIV, only 71 screened forHIV in a quality-
assuredmanner [45]. Thus, quality assurance and quality control
issues are other problems that continue to leave persistent gaps
in the blood safety chain in RLSs. It is vital that quality assurance
procedures be applied rigorously, and that procedures for
detecting errors be included in all testing protocols, tomaximize
the accuracy of the laboratory results. Where possible, labora-
tories should participate in annual external quality assessments.
Furthermore, the efforts to develop alternative, easily accessible
and affordable, in-country-adapted technologies, including
nucleic acid ampliﬁcation testing technologies, should be
fostered, to provide safe blood for all.
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